Oligoastrocytoma secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Overview
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and corticosteroid usage, checking for signs of venous thromboembolism, regular laboratory tests, and routine imaging (MRI and Positron Emission Tomography) at scheduled intervals after treatment.[1]
Secondary Prevention
Secondary Prevention
Follow up after treatment
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures for oligoastrocytoma include:[1]
- Clinical assessment of neurological function
- Tapering steroid usage as early as possible
- Checking for signs of venous thromboembolism
- Laboratory tests
- Generally not indicated, unless patient is on chemotherapy (complete blood count), steroids (glucose level), and anticonvulsants (complete blood count and liver function tests)
- MRI every 3-4 months
- Evaluation of tumor extension on T2 fluid-attenuated inversion recovery (FLAIR)-weighted MRI
- Positron emission tomography
References
References
- ↑ 1.0 1.1 Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). “High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH